Stereotactic surgery

Hologic Showcases New Breast Surgery Franchise at 20th Annual Meeting of The American Society of Breast Surgeons

Retrieved on: 
Tuesday, April 30, 2019
Surgery, Health, Medical devices, Oncology, Radiology, Medicine, Medical specialties, Clinical medicine, Breast surgery, Biopsy, RTT, Breast-conserving surgery, Breast cancer, Breast biopsy, Stereotactic surgery

Additionally, the Tag is designed to be implanted into the breast any time prior to the surgery, providing increased flexibility for patients and providers.

Key Points: 
  • Additionally, the Tag is designed to be implanted into the breast any time prior to the surgery, providing increased flexibility for patients and providers.
  • Additional hands-on workshops hosted by Hologic will cover topics such as stereotactic breast biopsy, oncoplastic skills and portable breast ultrasound.
  • Microchipping the breast: an effective new technology for localizing non-palpable breast lesions for surgery.
  • Poster presentation, Society of Surgical Oncology annual meeting, Mar 27-30, 2019.

GammaPod Stereotactic Radiotherapy System for Breast Cancer Receives CE Mark

Retrieved on: 
Thursday, April 25, 2019
Medicine, Medical specialties, Clinical medicine, Radiation therapy, Radiobiology, Neurosurgery, Medical physics, Breast cancer management, Stereotactic surgery, Radiosurgery, Breast cancer, Treatment of cancer

COLUMBIA, Md., April 25, 2019 /PRNewswire/ -- Xcision Medical Systems, LLC announced that the GammaPod stereotactic radiotherapy system has received CE marking, paving the way for new sales in Europe and offering patients the latest option in noninvasive breast cancer treatment.

Key Points: 
  • COLUMBIA, Md., April 25, 2019 /PRNewswire/ -- Xcision Medical Systems, LLC announced that the GammaPod stereotactic radiotherapy system has received CE marking, paving the way for new sales in Europe and offering patients the latest option in noninvasive breast cancer treatment.
  • "We are excited to bring GammaPod to the European market, where the need for more efficient, precise breast cancer radiotherapy treatments is increasing," said Cedric Yu, DSc, Xcision founder and chief executive officer.
  • With GammaPod, patients can receive partial breast radiation in conjunction with breast conserving treatment in five sessions or less.
  • GammaPod uses a first-of-its-kind breast cup immobilization system to minimize motion and provide high levels of accuracy for treatment planning and delivery.

ViewRay Announces Publication of Retrospective Study on MR-guided Radiation Treatment for Locally Advanced Pancreatic Cancer

Retrieved on: 
Thursday, April 11, 2019
Medicine, Medical specialties, Clinical medicine, Radiation therapy, Radiobiology, Neurosurgery, Gastrointestinal cancer, Pancreatic cancer, RTT, Stereotactic surgery, Retrospective cohort study

CLEVELAND, April 11, 2019 /PRNewswire/ --ViewRay, Inc. (Nasdaq: VRAY) announced today the publication of a retrospective analysis of outcomes for the stereotactic treatment of locally advanced pancreatic cancer using precise, high-dose MRI-guided radiation therapy delivered with MRIdian's on-table adaptive dose planning system.

Key Points: 
  • CLEVELAND, April 11, 2019 /PRNewswire/ --ViewRay, Inc. (Nasdaq: VRAY) announced today the publication of a retrospective analysis of outcomes for the stereotactic treatment of locally advanced pancreatic cancer using precise, high-dose MRI-guided radiation therapy delivered with MRIdian's on-table adaptive dose planning system.
  • "Locally advanced pancreatic cancer is notoriously difficult to treat, and the outcomes noted in this retrospective study are better than expected and very encouraging.
  • According to the publication, "The study was a multiinstitutional, retrospective, cohort study based on data from 5 institutions.
  • The SMART trial is designed to enroll 133 participants with borderline resectable or inoperable locally advanced pancreatic cancer.

The Radiosurgery Society® Recognizes Outstanding Residents for their Contributions to Radiosurgery Research

Retrieved on: 
Thursday, February 7, 2019
Medicine, Medical specialties, Radiation therapy, Clinical medicine, Neurosurgery, Radiobiology, Radiosurgery, Medical physics, Stereotactic surgery, SRS, Radiation oncologist, Cyberknife

SAN MATEO, Calif., Feb. 7, 2019 /PRNewswire-PRWeb/ --The Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science and clinical practice of radiosurgery, is recognizing eight medical residents and students for their outstanding contributions to research in the fields of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT).

Key Points: 
  • SAN MATEO, Calif., Feb. 7, 2019 /PRNewswire-PRWeb/ --The Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science and clinical practice of radiosurgery, is recognizing eight medical residents and students for their outstanding contributions to research in the fields of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT).
  • of Radiation Oncology, Henry Ford Cancer Institute at Henry Ford Health System and Advisor to the RSS Residents Committee.
  • The Radiosurgery Society (RSS) a non-profit, independent, multi-disciplinary organization of surgeons, radiation oncologists, physicists, and allied professionals, who are dedicated to advancing the science and clinical practice of radiosurgery.
  • Originally formed in 2002 and becoming (501c6) in 2008, the Radiosurgery Society today ( http://www.therss.org ) represents approximately 600 members who perform stereotactic body radiotherapy and radiosurgery in hospitals and freestanding centers throughout the world.

The Urology Group Surpasses 1,600 Prostate Cancer Patients Treated with the Accuray CyberKnife® M6™ System

Retrieved on: 
Thursday, January 17, 2019
Medicine, Radiation therapy, Neurosurgery, Surgery, Radiobiology, Cyberknife, Medical physics, Prostate cancer, Stereotactic surgery

SUNNYVALE, Calif., Jan. 17, 2019 /PRNewswire/ --According to the American Cancer Society, prostate cancer is the most common cancer in American men other than skin cancer.

Key Points: 
  • SUNNYVALE, Calif., Jan. 17, 2019 /PRNewswire/ --According to the American Cancer Society, prostate cancer is the most common cancer in American men other than skin cancer.
  • Accuray Incorporated (NASDAQ: ARAY) and The Urology Group (TUG) are partnering to recognize TUG's commitment to improving the lives of men with prostate cancer.
  • TUG physicians recently treated the center's 1,600th prostate cancer patient using the CyberKnife M6 System , a groundbreaking radiotherapy device that specializes in delivering stereotactic body radiation therapy (SBRT) treatments with sub-millimeter precision.
  • Published data continue to reinforce the benefits of CyberKnife SBRT for the treatment of low- and intermediate-risk prostate cancer.

Radiotherapy Market Worth $6.8 Billion by 2023 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 10, 2019
Medicine, Radiation therapy, Health, External beam radiotherapy, Stereotactic surgery, Therapy, Truebeam, Cyberknife

Based on type, the external beam Radiotherapy Market is classified into IGRT, IMRT, stereotactic therapy, particle beam therapy, and 3D-CRT.

Key Points: 
  • Based on type, the external beam Radiotherapy Market is classified into IGRT, IMRT, stereotactic therapy, particle beam therapy, and 3D-CRT.
  • The Radiotherapy Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World.
  • The North American region is expected to account for the largest share of the Radiotherapy Market in 2018.
  • Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM".

Radiotherapy Market Worth $6.8 Billion by 2023 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 10, 2019
Medicine, Radiation therapy, Health, External beam radiotherapy, Stereotactic surgery, Therapy, Truebeam, Cyberknife

Based on type, the external beam Radiotherapy Market is classified into IGRT, IMRT, stereotactic therapy, particle beam therapy, and 3D-CRT.

Key Points: 
  • Based on type, the external beam Radiotherapy Market is classified into IGRT, IMRT, stereotactic therapy, particle beam therapy, and 3D-CRT.
  • The Radiotherapy Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World.
  • The North American region is expected to account for the largest share of the Radiotherapy Market in 2018.
  • Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM".

Accuray CyberKnife® System Treatment Delivery Times Up to 50 Percent Faster With Software Upgrade

Retrieved on: 
Thursday, December 6, 2018
Medicine, Radiation therapy, Neurosurgery, Surgery, Radiobiology, Cyberknife, Radiosurgery, Medical physics, Stereotactic surgery, Reno CyberKnife

The next-generation TPS with the optimizer will facilitate the development of clinically optimal treatment plans up to 90 percent faster than before and the delivery of the treatment up to an estimated 50 percent faster than before, affording clinicians more time to expand patient access to the highly precise stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatments the CyberKnife System delivers.

Key Points: 
  • The next-generation TPS with the optimizer will facilitate the development of clinically optimal treatment plans up to 90 percent faster than before and the delivery of the treatment up to an estimated 50 percent faster than before, affording clinicians more time to expand patient access to the highly precise stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatments the CyberKnife System delivers.
  • The CyberKnife VOLO Optimizer builds on industry-established treatment planning methods with new tools intended to assist in delivering an exceptional clinical experience.
  • "We're thrilled with the results of our internal evaluation, which has shown noteworthy reductions in both treatment planning and delivery times compared to other TPS for the CyberKnife platform and treatment planning software for other delivery systems.
  • We believe the introduction of the CyberKnife VOLO Optimizer has the potential to significantly change the way the platform is used in clinical practice."

Multi-Center Study Shows Improved, Stable Clinical Outcomes in 96% of Patients with Brain METs

Retrieved on: 
Tuesday, October 9, 2018
Medicine, Brain tumor, Clinical medicine, Neurosurgery, Radiation therapy, Nervous system, Radiobiology, Radiosurgery, Brain metastasis, Allan Hamilton, Stereotactic surgery

"Patients with symptomatic brain metastases with surrounding edema have traditionally been optimal radiosurgery targets.

Key Points: 
  • "Patients with symptomatic brain metastases with surrounding edema have traditionally been optimal radiosurgery targets.
  • In this study, such patients underwent safe resection and [gross total resection] GTR was achieved in 80 percent of the cases," Dr. Zada said.
  • "In each case, surgery provided a more compact and suitable target for radiosurgery and also enabled definitive diagnosis."
  • It is an outcomes-based company dedicated to revolutionizing minimally invasive neurosurgery through evidence-based, improved clinical and economic outcomes.

Varian Signs Educational Partnerships with Reliance Group in India

Retrieved on: 
Thursday, October 4, 2018
Medicine, Radiation therapy, Clinical medicine, Radiobiology, Neurosurgery, Medical physics, Radiosurgery, Kokilaben Dhirubhai Ambani Hospital, Radiation oncologist, Tina Ambani, Stereotactic surgery, Ambani

The clinical school is aimed at radiation oncologists, medical physicists and radiation therapy technologists in India.

Key Points: 
  • The clinical school is aimed at radiation oncologists, medical physicists and radiation therapy technologists in India.
  • "By collaborating with KDAH and the Reliance Group in this way, we hope to make a meaningful difference to radiotherapy and radiosurgery expertise in India and move a step closer to our goal of creating a world free from the fear of cancer," added Ashok Kakkar, senior managing director of Varian India.
  • "We are proud to partner with Varian for the first stereotactic school in the region," said Tina Ambani, chairperson of Kokilaben Hospital & Reliance Hospitals Group.
  • Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer.